DA 8031

Drug Profile

DA 8031

Alternative Names: DA8031

Latest Information Update: 16 Dec 2015

Price : $50

At a glance

  • Originator Dong-A Pharmaceutical
  • Developer Dong-A ST
  • Class Benzofurans
  • Mechanism of Action Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Premature ejaculation

Highest Development Phases

  • Phase II Premature ejaculation

Most Recent Events

  • 16 Dec 2015 Phase-II development for Premature ejaculation is ongoing in South Korea
  • 01 Jan 2013 Phase-II clinical trials in Premature ejaculation in South Korea (PO)
  • 31 Oct 2011 Dong-A Pharmaceuticals completes a phase I trial in Healthy volunteers in South Korea (NCT01104948)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top